SCHEMBL433952

SCHEMBL433952

Cc1cc2c(C)cccc2o1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 10/20 0.46
▸ CYP2A6 P11509 3/20 0.46
▸ CYP1A1 P04798 5/20 0.46
▸ CYP1B1 Q16678 5/20 0.46
▸ MAOA P21397 1/20 0.41
▸ ALDH1A1 P00352 5/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ACHE P22303 2/20 0.38
▸ HPGD P15428 3/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ HSD17B10 Q99714 2/20 0.35
▸ TP53 P04637 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12778694 0.78 CYP1A2 (0.43) CYP1A2CYP1A1CYP1B1MAOAALDH1A1
SCHEMBL8286028 0.78 AHR (0.42) CYP1A2CYP2A6CYP1A1CYP1B1ALDH1A1
SCHEMBL12778723 0.78 EYA3 (0.41) CYP1A2CYP1A1CYP1B1ALDH1A1LMNA
SCHEMBL2268151 0.78 MAOA (0.44) CYP1A2CYP1A1CYP1B1MAOASMN1; SMN2
SCHEMBL12728518 0.78 CYP1A1 (0.40) CYP1A2CYP1A1CYP1B1SMN1; SMN2ACHE
SCHEMBL5035815 0.78 CYP1A1 (0.40) CYP1A2CYP1A1CYP1B1MAOAALDH1A1
SCHEMBL20125051 0.78 NQO1 (0.42) CYP1A2CYP1A1CYP1B1ALDH1A1SMN1; SMN2
SCHEMBL23218380 0.78 CYP1A2 (0.42) CYP1A2CYP2A6MAOAALDH1A1SMN1; SMN2
SCHEMBL27921495 0.78 CYP1A2 (0.42) CYP1A2CYP2A6MAOAALDH1A1SMN1; SMN2
SCHEMBL4120120 0.78 CYP1A2 (0.53) CYP1A2CYP1A1CYP1B1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239824-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-18 — — US disclosed
US-20240244950-A1 ORGANIC LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-18 — — US disclosed
US-20240244858-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-18 — — US disclosed
US-20240237507-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG ELECTRONICS CO LTD (KR) 2024-07-11 — — US disclosed
US-20240224786-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-04 — — US disclosed
US-20240224785-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-04 — — US disclosed
US-20240074303-A1 DISPLAY APPARATUS SAMSUNG DISPLAY CO., LTD. (KR) 2024-02-29 — — US disclosed
US-20240067669-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2024-02-29 — — US disclosed
US-20240074300-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2024-02-29 — — US disclosed
US-11912724-B2 Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device SAMSUNG ELECTRONICS CO., LTD. (KR) 2024-02-27 — — US disclosed
US-20100266556-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2010-10-21 — — US disclosed
EP-2218716-A1 METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND Nissan Chemical Industries, Ltd. (JP) 2010-08-18 — — EP disclosed
US-20100184808-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2010-07-22 — — US disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — US disclosed
US-20090192154-A1 SULTAM DERIVATIVES ASAHI KASEI PHARMA CORPORATION (JP) 2009-07-30 — — US disclosed
WO-2009004584-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2009-01-08 — — WO disclosed
US-7326729-B2 CXCR1 and CXCR2 chemokine antagonists SCHERING CORPORATION (US) 2008-02-05 — — US disclosed
US-20070248594-A1 CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS SCHERING CORPORATION 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067669-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE C1S, CHRM1, C1R CYP1A2 466/4885CYP2A6 1378/4885CYP1A1 79/4885
US-20240074300-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE C1S, C1R, CHRM1 CYP1A2 709/4885CYP2A6 2211/4885CYP1A1 137/4885
US-20240224786-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CHRM1, CHRM4, CYBA CYP1A2 409/4885CYP2A6 569/4885CYP1A1 46/4885
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 CYP1A2 585/4885CYP2A6 893/4885CYP1A1 549/4885
US-11912724-B2 Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device L1CAM, FOXM1, CHRM1 CYP1A2 98/4885CYP2A6 835/4885CYP1A1 32/4885
US-20100266556-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND HCLS1, RUNX1, ACIN1 CYP1A2 2808/4885CYP2A6 2755/4885CYP1A1 812/4885
US-20240224785-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE C1S, CHRM1, C5 CYP1A2 273/4885CYP2A6 643/4885CYP1A1 51/4885
US-20240244950-A1 ORGANIC LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME EML4, DNMT3L, LIN28A CYP1A2 1238/4885CYP2A6 2799/4885CYP1A1 1089/4885
US-20070248594-A1 CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS CXCR1, CXCR2, CXCR5 CYP1A2 2928/4885CYP2A6 2937/4885CYP1A1 2917/4885
US-20100184808-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS HCRTR2, HCRTR1, OXTR CYP1A2 518/4885CYP2A6 798/4885CYP1A1 413/4885
US-20240244858-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CRY1, CRY2, C1S CYP1A2 181/4885CYP2A6 1318/4885CYP1A1 52/4885
US-20240239824-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE C1S, CHRM1, L1CAM CYP1A2 142/4885CYP2A6 1246/4885CYP1A1 27/4885
US-20240237507-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE L1CAM, MSL1, EML4 CYP1A2 506/4885CYP2A6 1325/4885CYP1A1 130/4885
US-20090192154-A1 SULTAM DERIVATIVES SULT1A1, SULT2A1, ADAMTS1 CYP1A2 1655/4885CYP2A6 1111/4885CYP1A1 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback